Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.…
Absci Corp. (ABSI) Gets Downgraded. Here’s How Much
Absci (NASDAQ: ABSI) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 140 employees.
The shares were at 7.510 USD on 20 November 2026, up 71.9% over 52 weeks. Its 52-week range is 2.240 USD to 12.54 USD: the price is 40.1% below the high and 235.3% above the low.
Its market capitalisation is 1.30B USD.
Absci reports return on equity of -60.8% and revenue down 19.6% year over year.
It holds more cash than debt, a net cash position of 170.44M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 11 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 15.09 USD is 100.9% above the current price. The next earnings report is expected on 23 March 2027.